Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2020

Open Access 01-12-2020 | Colorectal Cancer | Research article

ZBTB7A functioned as an oncogene in colorectal cancer

Authors: Li Wang, Meng-Xia Zhang, Mei-Fang Zhang, Zi-Wei Tu

Published in: BMC Gastroenterology | Issue 1/2020

Login to get access

Abstract

Background

Despite zinc finger and BTB domain-containing 7A (ZBTB7A) documented importance in multiple tumors, the function and clinical value in Colorectal cancer (CRC) remain elusive. The aim of this study was to evaluate the functional roles and the clinical value of ZBTB7A in CRC progression.

Methods

The level of ZBTB7A was detected in a large cohort of CRC patients (n = 189) by immunohistochemistry (IHC), and we analyzed the diagnostic and prognostic value of the protein. In addition, the functional roles of ZBTB7A on CRC were explored in vitro and in vivo.

Results

Survival analyses indicated that patients with high ZBTB7A expression made the prognosis worse (P = 0.024). Functionally, knockdown of ZBTB7A could markedly inhibit tumor proliferation in vitro and in vivo, whereas ZBTB7A overexpression displayed the opposite results.

Conclusions

ZBTB7A was associated with poor survival outcomes and functioned as an oncogene in CRC patients, indicating that it is a potential prognostic biomarker and therapeutic target for CRC patients.
Appendix
Available only for authorised users
Literature
1.
2.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
3.
Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut. 2011;60(1):116–29.CrossRefPubMed
4.
Raut JR, Guan Z, Schrotz-King P, Brenner H. Whole-blood DNA Methylation Markers for Risk Stratification in Colorectal Cancer Screening: A Systematic Review. Cancers. 2019;11(7):912.
5.
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–80.CrossRefPubMed
6.
Shirmohamadi M, Eghbali E, Najjary S, Mokhtarzadeh A, Kojabad AB, Hajiasgharzadeh K, Lotfinezhad P, Baradaran B. Regulatory mechanisms of microRNAs in colorectal cancer and colorectal cancer stem cells. J Cell Physiol. 2020;235(2):776–89.CrossRefPubMed
7.
Bird NC, Mangnall D, Majeed AW. Biology of colorectal liver metastases: a review. J Surg Oncol. 2006;94(1):68–80.CrossRefPubMed
8.
Yang XM, You HY, Li Q, Ma H, Wang YH, Zhang YL, Zhu L, Nie HZ, Qin WX, Zhang ZG, et al. CTHRC1 promotes human colorectal cancer cell proliferation and invasiveness by activating Wnt/PCP signaling. Int J Clin Exp Pathol. 2015;8(10):12793–801.PubMedPubMedCentral
9.
Maeda T, Hobbs RM, Pandolfi PP. The transcription factor Pokemon: a new key player in cancer pathogenesis. Cancer Res. 2005;65(19):8575–8.CrossRefPubMed
10.
11.
Davies JM, Hawe N, Kabarowski J, Huang QH, Zhu J, Brand NJ, Leprince D, Dhordain P, Cook M, Morriss-Kay G, et al. Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene. Oncogene. 1999;18(2):365–75.CrossRefPubMed
12.
Apostolopoulou K, Pateras IS, Evangelou K, Tsantoulis PK, Liontos M, Kittas C, Tiniakos DG, Kotsinas A, Cordon-Cardo C, Gorgoulis VG. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer. J Pathol. 2007;213(3):294–302.CrossRefPubMed
13.
Zhijun Z, Jingkang H. MicroRNA-520e suppresses non-small-cell lung cancer cell growth by targeting Zbtb7a-mediated Wnt signaling pathway. Biochem Biophys Res Commun. 2017;486(1):49–56.CrossRefPubMed
14.
Mao A, Chen M, Qin Q, Liang Z, Jiang W, Yang W, Wei C. ZBTB7A promotes migration, invasion and metastasis of human breast cancer cells through NF-kappaB-induced epithelial-mesenchymal transition in vitro and in vivo. J Biochem. 2019;166(6):485–93.CrossRefPubMed
15.
Yeh LY, Yang CC, Wu HL, Kao SY, Liu CJ, Chen YF, Lin SC, Chang KW. The miR-372-ZBTB7A oncogenic axis suppresses TRAIL-R2 associated drug sensitivity in oral carcinoma. Front Oncol. 2020;10:47.CrossRefPubMedPubMedCentral
16.
Jiang L, Siu MK, Wong OG, Tam KF, Lam EW, Ngan HY, Le XF, Wong ES, Chan HY, Cheung AN. Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers. Mol Cancer. 2010;9:318.CrossRefPubMedPubMedCentral
17.
Liu XS, Genet MD, Haines JE, Mehanna EK, Wu S, Chen HI, Chen Y, Qureshi AA, Han J, Chen X, et al. ZBTB7A suppresses melanoma metastasis by transcriptionally repressing MCAM. Mol Cancer Res. 2015;13(8):1206–17.CrossRefPubMedPubMedCentral
18.
Han D, Chen S, Han W, Gao S, Owiredu JN, Li M, Balk SP, He HH, Cai C. ZBTB7A mediates the transcriptional repression activity of the androgen receptor in prostate cancer. Cancer Res. 2019;79(20):5260–71.PubMedPubMedCentral
19.
Joo JW, Kim HS, Do SI, Sung JY. Expression of zinc finger and BTB domain-containing 7A in colorectal carcinoma. Anticancer Res. 2018;38(5):2787–92.PubMed
20.
Zhao GT, Yang LJ, Li XX, Cui HL, Guo R. Expression of the proto-oncogene Pokemon in colorectal cancer--inhibitory effects of an siRNA. Asian Pac J Cancer Prev. 2013;14(9):4999–5005.CrossRefPubMed
21.
Zhu M, Li M, Zhang F, Feng F, Chen W, Yang Y, Cui J, Zhang D, Linghu E. FBI-1 enhances ETS-1 signaling activity and promotes proliferation of human colorectal carcinoma cells. PLoS One. 2014;9(5):e98041.CrossRefPubMedPubMedCentral
22.
Zhao Y, Yao YH, Li L, An WF, Chen HZ, Sun LP, Kang HX, Wang S, Hu XR. Pokemon enhances proliferation, cell cycle progression and anti-apoptosis activity of colorectal cancer independently of p14ARF-MDM2-p53 pathway. Med Oncol. 2014;31(12):288.CrossRefPubMed
23.
Wang Z, Zhao X, Wang W, Liu Y, Li Y, Gao J, Wang C, Zhou M, Liu R, Xu G, et al. ZBTB7 evokes 5-fluorouracil resistance in colorectal cancer through the NFkappaB signaling pathway. Int J Oncol. 2018;53(5):2102–10.PubMed
24.
Molloy ME, Lewinska M, Williamson AK, Nguyen TT, Kuser-Abali G, Gong L, Yan J, Little JB, Pandolfi PP, Yuan ZM. ZBTB7A governs estrogen receptor alpha expression in breast cancer. J Mol Cell Biol. 2018;10(4):273–84.CrossRefPubMedPubMedCentral
25.
Ramos Pittol JM, Oruba A, Mittler G, Saccani S, van Essen D. Zbtb7a is a transducer for the control of promoter accessibility by NF-kappa B and multiple other transcription factors. PLoS Biol. 2018;16(5):e2004526.CrossRefPubMedPubMedCentral
26.
Zhang L, Wang Y, Li X, Xia X, Li N, He R, He H, Han C, Zhao W. ZBTB7A enhances osteosarcoma chemoresistance by transcriptionally repressing lncRNALINC00473-IL24 activity. Neoplasia. 2017;19(11):908–18.CrossRefPubMedPubMedCentral
27.
Zhu M, Wang P, Feng F, Li MY. LRF inhibits p53 expression in colon cancer cells via modulating DAP5 activity. Cell Biochem Funct. 2017;35(7):401–6.CrossRefPubMed
Metadata
Title
ZBTB7A functioned as an oncogene in colorectal cancer
Authors
Li Wang
Meng-Xia Zhang
Mei-Fang Zhang
Zi-Wei Tu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2020
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-020-01456-z

Other articles of this Issue 1/2020

BMC Gastroenterology 1/2020 Go to the issue

Case report

Conservative recovery and replacement of a ruptured percutaneous endoscopic gastrostomy tube; a case report

Research article

Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

Research article

Impact of symptom severity in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D): results from two separate surveys of HCPs and patients with IBS-D

Research article

Underwater versus conventional endoscopic mucosal resection for small size non-pedunculated colorectal polyps: a randomized controlled trial

Research article

Efficacy of gastric decompression after pancreatic surgery: a systematic review and meta-analysis

Case report

Primary abdominal cocoon with cryptorchidism: a case report
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits